Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Non-Current Assets (2020 - 2025)

Bolt Biotherapeutics' Non-Current Assets history spans 6 years, with the latest figure at $29.4 million for Q3 2025.

  • For Q3 2025, Non-Current Assets fell 43.57% year-over-year to $29.4 million; the TTM value through Sep 2025 reached $158.8 million, down 21.26%, while the annual FY2024 figure was $48.8 million, 9.72% down from the prior year.
  • Non-Current Assets for Q3 2025 was $29.4 million at Bolt Biotherapeutics, down from $37.2 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $118.6 million in Q4 2021 and bottomed at $29.4 million in Q3 2025.
  • The 5-year median for Non-Current Assets is $54.1 million (2023), against an average of $64.1 million.
  • The largest annual shift saw Non-Current Assets skyrocketed 459.74% in 2021 before it plummeted 53.56% in 2022.
  • A 5-year view of Non-Current Assets shows it stood at $118.6 million in 2021, then tumbled by 53.56% to $55.1 million in 2022, then dropped by 1.79% to $54.1 million in 2023, then decreased by 9.72% to $48.8 million in 2024, then plummeted by 39.68% to $29.4 million in 2025.
  • Per Business Quant, the three most recent readings for BOLT's Non-Current Assets are $29.4 million (Q3 2025), $37.2 million (Q2 2025), and $43.4 million (Q1 2025).